Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LuCa-MERIT-1: BNT116 Alone and in Combinations in Advanced Non-small Cell Lung Cancer
NCT05142189Phase 1Recruiting
- Sponsor
- BioNTech SE
- Start
- Jun 2022
- Primary completion
- Feb 2030
- Modality
- Therapeutic Vaccines, mRNA Therapeutics
- Countries
- 8
01
Overview
Phase 1, open-label trial of BNT116 in non-small cell lung cancer (NSCLC) (14 cohorts), sponsored by BioNTech SE. Primary endpoints: Dose-Limiting Toxicities at 21 days, Treatment-Emergent Adverse Events at 27 months and 2 more. Started Jun 2022; status: recruiting.
02
Drugs
BNT116
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05142189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05142189.